The discrepancy between mouse and human studies (and indeed, among human data) as to whether the CD4+ or CD4− iNKT population is best suited to reduce GVHD (and possible differences between acute and chronic GVHD) highlights the need for further study. This evidence concerns the gene CD4 and chronic graft versus host disease.